These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 9475111)
21. Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection. Bhana N; Ormrod D; Perry CM; Figgitt DP Paediatr Drugs; 2002; 4(8):515-53. PubMed ID: 12126455 [TBL] [Abstract][Full Text] [Related]
22. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429 [TBL] [Abstract][Full Text] [Related]
24. Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries. Dalpiaz A; Fogagnolo M; Ferraro L; Capuzzo A; Pavan B; Rassu G; Salis A; Giunchedi P; Gavini E Antiviral Res; 2015 Nov; 123():146-57. PubMed ID: 26427553 [TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study. Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834 [TBL] [Abstract][Full Text] [Related]
26. The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. Anthonypillai C; Sanderson RN; Gibbs JE; Thomas SA J Pharmacol Exp Ther; 2004 Mar; 308(3):912-20. PubMed ID: 14634041 [TBL] [Abstract][Full Text] [Related]
27. Distribution of valproate to subdural cerebrospinal fluid, subcutaneous extracellular fluid, and plasma in humans: a microdialysis study. Lindberger M; Tomson T; Wallstedt L; Ståhle L Epilepsia; 2001 Feb; 42(2):256-61. PubMed ID: 11240599 [TBL] [Abstract][Full Text] [Related]
28. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. Fletcher CV; Anderson PL; Kakuda TN; Schacker TW; Henry K; Gross CR; Brundage RC AIDS; 2002 Mar; 16(4):551-60. PubMed ID: 11872998 [TBL] [Abstract][Full Text] [Related]
29. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822 [TBL] [Abstract][Full Text] [Related]
30. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Cihlar T; Ray AS Antiviral Res; 2010 Jan; 85(1):39-58. PubMed ID: 19887088 [TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Foudraine NA; Hoetelmans RM; Lange JM; de Wolf F; van Benthem BH; Maas JJ; Keet IP; Portegies P Lancet; 1998 May; 351(9115):1547-51. PubMed ID: 10326538 [TBL] [Abstract][Full Text] [Related]
32. In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. Takasawa K; Terasaki T; Suzuki H; Sugiyama Y J Pharmacol Exp Ther; 1997 Apr; 281(1):369-75. PubMed ID: 9103519 [TBL] [Abstract][Full Text] [Related]
33. Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. Martin C; Sönnerborg A; Svensson JO; Ståhle L AIDS; 1999 Jul; 13(10):1227-32. PubMed ID: 10416527 [TBL] [Abstract][Full Text] [Related]
34. 3'-Azido-2',3'-dideoxythymidine (zidovudine) uptake mechanisms in T lymphocytes. Purcet S; Minuesa G; Molina-Arcas M; Erkizia I; Casado FJ; Clotet B; Martinez-Picado J; Pastor-Anglada M Antivir Ther; 2006; 11(6):803-11. PubMed ID: 17310825 [TBL] [Abstract][Full Text] [Related]
35. Equilibrium distribution of HIV antiviral drugs into human peripheral blood mononuclear cells (PBMC) is controlled by free drug concentration in the extracellular medium. Koeplinger KA; Raub TJ; Padbury GE; Zhao Z J Pharm Biomed Anal; 1999 Mar; 19(3-4):399-411. PubMed ID: 10704105 [TBL] [Abstract][Full Text] [Related]
36. Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains. Yu F; Li W; Wang L; Dai Y; Lu X; Wang Q; Xie L; Jiang S Molecules; 2018 Jul; 23(7):. PubMed ID: 30004408 [TBL] [Abstract][Full Text] [Related]
37. Synthesis, in vitro biological stability, and anti-HIV activity of 5-halo-6-alkoxy(or azido)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs to 3'-azido-3'-deoxythymidine (AZT). Kumar R; Wang L; Wiebe LI; Knaus EE J Med Chem; 1994 Dec; 37(25):4297-306. PubMed ID: 7996541 [TBL] [Abstract][Full Text] [Related]
38. Penetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action. Ljungdahl-Ståhle E; Guzenda E; Böttiger D; Wahren B; Oberg B; Ståhle L Antimicrob Agents Chemother; 1992 Nov; 36(11):2418-22. PubMed ID: 1489185 [TBL] [Abstract][Full Text] [Related]
39. Anti-HIV drug distribution to the central nervous system. Thomas SA Curr Pharm Des; 2004; 10(12):1313-24. PubMed ID: 15134483 [TBL] [Abstract][Full Text] [Related]